Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging

Investigative Radiology

Volumn 46, Issue 4, 2011, Pages 277-283

  Katsube, Takashi ^a   Okada, Masahiro ^b   Kumano, Seishi ^b   Hori, Masatoshi ^c   Imaoka, Izumi ^b   Ishii, Kazunari ^b   Kudo, Masatoshi ^b   Kitagaki, Hajime ^a   Murakami, Takamichi ^b  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gd EOB DTPA; liver function; T1 mapping

Indexed keywords

GADOXETIC ACID;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; STUDENT T TEST; T1 MAPPING;

EID: 79952444250     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e318200f67d     Document Type: Article

References (45)

1. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOBDTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology. 1995;195:785-792.
2. Mühler A, Heinzelmann I, Weinmann HJ. Elimination of gadolinium-ethoxybenzyl- DTPA in a rat model of severely impaired liver and kidney excretory function. An experimental study in rats. Invest Radiol. 1994;29:213-216. (Pubitemid 24099852)
3. Saito K, Kotake F, Ito N, et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci. 2005;4:1-9.
4. Fujita M, Yamamoto R, Fritz-Zieroth B, et al. Contrast enhancement with Gd-EOB-DTPA in MR imaging of hepatocellular carcinoma in mice: a comparison with superparamagnetic iron oxide. J Magn Reson Imaging. 1996;6:472-477. (Pubitemid 126707482)
5. Bluemke DA, Sahani D, Amendola M, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U. S. multicenter phase III study.Radiology. 2005;237:89-98. (Pubitemid 41346150)
6. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology. 2004;230:266-275. (Pubitemid 37549812)
7. Sun HY, Lee JM, Shin CI, et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (-2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol. 2010;45:96-103.
8. Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrastenhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol. 2010;45:133-141.
9. Tsuda N, Okada M, Murakami T. Potential of gadolinium- ethoxybenzyldiethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol. 2007;42:242-247. (Pubitemid 46398863)
10. Shimizu J, Dono K, Gotoh M, et al. Evaluation of regional liver function by gadolinium-EOB-DTPA-enhanced MR imaging. Dig Dis Sci. 1999;44:1330-1337. (Pubitemid 29404293)
11. Schmitz SA, Muhler A, Wagner S, et al. Functional hepatobiliary imaging with gadolinium-EOB-DTPA. A comparison of magnetic resonance imaging and 153gadolinium-EOB-DTPA scintigraphy in rats. Invest Radiol. 1996;31: 154-160.
12. Ryeom HK, Kim SH, Kim JY, et al. Quantitative evaluation of liver function with MRI Using Gd-EOB-DTPA. Korean J Radiol. 2004;5:231-239.
13. Kim T, Murakami T, Hasuike Y, et al. Experimental hepatic dysfunction: evaluation by MRI with Gd-EOB-DTPA. J Magn Reson Imaging. 1997;7: 683-688. (Pubitemid 28365618)
14. Motosugi U, Ichikawa T, Sou H, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging. 2009;30:1042-1046.
15. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology. 1988; 95:734-739.
16. Luo JC, Hwang SJ, Chang FY, et al. Simple blood tests can predict compensated liver cirrhosis in patients with chronic hepatitis C. Hepatogastroenterology. 2002;49:478-481.
17. Gaiani S, Gramantieri L, Venturoli N, et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol. 2003;39:222-230.
18. Obrador BD, Prades MG, Gomez MV, et al. A predictive index for the diagnosis of cirrhosis in hepatitis C based on clinical, laboratory, and ultrasound findings. Eur J Gastroenterol Hepatol. 2006;18:57-62. (Pubitemid 43004882)
19. Kudo M, Zheng RQ, Kim SR, et al. Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis. Intervirology. 2008;51:17-26. (Pubitemid 351821838)
20. Look DC, Locker DR. Time saving in measurement of NMR and EPR relacation times. Rev Sci Instum. 1970;41:250-251.
21. Kay I, Henkelman RM. Practical implementation and optimization of oneshot T1 imaging. Magn Reson Med. 1991;22:414-424.
22. Horsthuis K, Nederveen AJ, de Feiter MW, et al. Mapping of T1-values and Gadolinium-concentrations in MRI as indicator of disease activity in luminal Crohn's disease: a feasibility study. J Magn Reson Imaging. 2009;29:488-493.
23. Thomsen C, Christoffersen P, Henriksen O, et al. Prolonged T1 in patients with liver cirrhosis: an in vivo MRI study. Magn Reson Imaging. 1990; 8:599-604. (Pubitemid 20321976)
24. Doyle FH, Pennock JM, Banks LM, et al. Nuclear magnetic resonance imaging of the liver: initial experience. Am J Roentgenol. 1982;138:193-200. (Pubitemid 12163119)
25. Smith FW, Mallard JR. NMR imaging in liver disease. Br Med Bull. 1984;40:194-196. (Pubitemid 14137787)
26. Stark DD, Bass NM, Moss AA, et al. Nuclear magnetic resonance imaging of experimentally induced liver disease. Radiology. 1983;148:743-751. (Pubitemid 13033798)
27. Goldberg HI, Moss AA, Stark DD, et al. Hepatic cirrhosis: magnetic resonance imaging. Radiology. 1984;153:737-739. (Pubitemid 15190051)
28. The Clinical NMR Group. Magnetic resonance imaging of parenchymal liver disease: a comparison with ultrasound, radionuclide scintigraphy and X-ray computed tomography. Clin Radiol. 1987;38:495-502.
29. Pascolo L, Cupelli F, Anelli PL, et al. Molecular mechanisms for the hepatic uptake of magnetic resonance imaging contrast agents. Biochem Biophys Res Commun. 1999;257:746-752. (Pubitemid 29301512)
30. van Montfoort JE, Stieger B, Meijer DK, et al. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther. 1999;290:153-157. (Pubitemid 29302315)
31. Geier A, Dietrich CG, Voigt S, et al. Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis. Hepatology. 2003;38:345-354. (Pubitemid 36919855)
32. Geier A, Kim SK, Gerloff T, et al. Hepatobiliary organic anion transporters are differentially regulated in acute toxic liver injury induced by carbon tetrachloride. J Hepatol. 2002;37:198-205. (Pubitemid 34833081)
33. Planchamp C, Montet X, Frossard JL, et al. Magnetic resonance imaging with hepatospecific contrast agents in cirrhotic rat livers. Invest Radiol. 2005;40: 187-194. (Pubitemid 40393229)
34. Kojima H, Nies AT, Konig j, et al. Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. J Hepatol. 2003;39:693-702. (Pubitemid 37372176)
35. Taura K, Ikai I, Hatano E, et al. Influence of coexisting cirrhosis on outcomes after partial hepatic resection for hepatocellular carcinoma fulfilling the Milan criteria: an analysis of 293 patients. Surgery. 2007;142:685-694. (Pubitemid 350018839)
36. Ng KK, Poon RT, Lo CM, et al. Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J Gastrointest Surg. 2008;12:183-191.
37. Taniguchi M, Kim SR, Imoto S, et al. Long-term outcome of percutaneous ethanol injection therapy for minimum-sized hepatocellular carcinoma. World J Gastroenterol. 2008;14:1997-2002. (Pubitemid 351795818)
38. Danila M, Sporea I, Sirli R, et al. Percutaneous ethanol injection therapy in the treatment of hepatocarcinoma-results obtained from a series of 88 cases. J Gastrointestin Liver Dis. 2009;18:317-322.
39. Yip WM, Hung HG, Lok KH, et al. Outcome of inoperable hepatocellular carcinoma patients receiving transarterial chemoembolisation: a real-life retrospective analysis in a Hong Kong regional hospital. Hong Kong Med J. 2009;15:339-345.
40. Seyama Y, Kokudo N. Assessment of liver function for safe hepatic resection. Hepatol Res. 2009;39:107-116.
41. Lau H, Man K, Fan ST, et al. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg. 1997;84:1255-1259. (Pubitemid 27400276)
42. Matsumata T, Kanematsu T, Yoshida Y, et al. The indocyanine green test enables prediction of postoperative complications after hepatic resection. World J Surg. 1987;11:678-681.
43. Takao H, Akai H, Tajima T, et al. MR imaging of the biliary tract with Gd-EOB-DTPA: effect of liver function on signal intensity. Eur J Radiol. 2011;77;325-329.
44. de Bazelaire CM, Duhamel GD, Rofsky NM, et al. MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results. Radiology. 2004;230:652-659. (Pubitemid 38252858)
45. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology. 1996; 199:177-183. (Pubitemid 26098637)